A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors

This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation study assessed BI 860585 monotherapy (5-300 mg/day; Arm A), BI 860585 (40-220 mg/day; Arm B) with 25 mg/day exemestane, and BI 860585 (80-220 mg/day; Arm C) with 60-80 mg/m(2)/week paclitaxel, in 28-day cycles. Primary endpoints were the number of patients with dose-limiting toxicities (DLTs) in cycle 1 and the MTD. Forty-one, 25, and 24 patients were treated (Arms A, B, and C). DLTs were observed in four (rash (n= 2), elevated alanine aminotransferase/aspartate aminotransferase, diarrhea), four (rash (n= 3), stomatitis, and increased gamma-glutamyl transferase), and two (diarrhea, increased blood creatine phosphokinase) patients in cycle 1. The BI 860585 MTD was 220 mg/day (Arm A) and 160 mg/day (Arms B and C). Nine patients achieved an objective response (Arm B: Four partial responses (PRs); Arm C: Four PRs; one complete response). The disease control rate was 20%, 28%, and 58% (Arms A, B, and C). The most frequent treatment-related adverse events (AEs) were hyperglycemia (54%) and diarrhea (39%) (Arm A); diarrhea (40%) and stomatitis (40%) (Arm B); fatigue (58%) and diarrhea (58%) (Arm C). The MTD was determined in all arms. Antitumor activity was observed with BI 860585 monotherapy and in combination with exemestane or paclitaxel

Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.

The characteristics of the binding of [3H]paroxetine, a selective serotonin (5-HT) uptake blocker, were investigated in human brain. The Kd value was 0.23 +/- 0.07 nM, and the Bmax value was 190 +/- 39 fmol/mg protein in the putamen. The capacity of various antidepressive drugs to inhibit [3H]paroxetine-specific binding in human brain was well correlated with their capacity to inhibit [3H]5-HT uptake in rat brain. The highest concentrations of [3H]paroxetine-specific binding sites were found in the substantia nigra, hypothalamus, and hippocampus. Lower values were obtained in the basal ganglia and the thalamus. The specific binding was very low in cerebral and cerebellar cortices. The regional distribution of [3H]paroxetine binding sites differs from that of [3H]ketanserin binding to S2 serotonin receptors. The subcellular distribution of the [3H]paroxetine-specific binding sites obtained by differential centrifugation revealed a synaptosomal enrichment in the frontal cortex and striatum, whereas an enrichment in the microsomal fraction was found in striatum. The results show that [3H]paroxetine is a ligand of choice to label the 5-HT uptake molecular complex in human brain

Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment

Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological syndrome characterized by acute hypertension, headache, decreased level of consciousness, visual disturbances and seizures associated with characteristic neuroimaging changes indicative of vasogenic edema of the posterior cerebral white matter. Several medical conditions have been associated with PRES including hypertensive encephalopathy and eclampsia. The use of cytotoxic and immunosuppressant drugs, such as those which target vascular endothelial growth factor (VEGF), have also been implicated. We report here the case of a 71-year-old woman with metastatic clear cell renal carcinoma who developed PRES 3 months after commencing sorafenib. Elevated blood pressure (BP) was recorded, and MRI of the brain) of the brain showed asymmetric areas of increased signal intensity within the supratentorial white matter suggestive of PRES. Clinical and radiological features rapidly improved with BP control and discontinuation of sorafenib. Sorafenib was resumed with no sign of PRES recurrence. The present case report supports the hypothesis that, in selected patients, the re-introduction of anti-VEGF therapies after PRES is feasible

Le SIDA: indications d'IAD ?

info:eu-repo/semantics/nonPublishe

Le SIDA :indication d'insémination artificielle avec sperme de donneur anonyme ?

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Collège de Belgique, février-mars 2012

Hétérogénéité des savoirs scientifiques, épistémologie générique et non-philosophi

A generic land to sea modelling chain for fighting coastal eutrophication in France

International audienceWater-authorities are prompt to consider coastal eutrophication in their management of water quality. Identifying admissible nutrient thresholds remains highly uncertain considering the complexity of biogeochemical processes involved in carbon and nutrient cycling that can either attenuate or exacerbate the imbalance in nutrients cascading from land to the coastal waters. A modelling chain including agricultural practices (GRAFS model), the transfer and transformations of carbon and nutrients along the hydrographic network (pyNuts-Riverstrahler model) and estuaries (C-GEM model) was designed and applied, for the first time at the scale of the entire metropolitan France, over the 2014-2019 period. Using a large database of riverine measurements (n=392,870 data from 929 stations), the results were validated for dissolved organic carbon (DOC), nitrate (NO3), dissolved phosphorus (PO4), total phosphorus (TP) and dissolved silica (DSi). This land-to-sea modelling chain allows identifying the origin of nutrient excess exported to coastal waters where it supports harmful algae blooms. Our work provides an accurate source apportionment of nutrients for 64 French sea outlets and demonstrates that efforts are still needed to reduce diffuse agricultural nutrients loads. Thanks to process-based and spatially explicit modelling tools, our approach identifies and quantifies the main processes governing the transfer of nutrients along the aquatic continuum and should ultimately sheds light on achievable levels of nutrients in marine and coastal areas